CF PharmTech, Inc. disclosed that it repurchased 49,500 H-shares on 21 May 2026 through on-exchange transactions. The buyback was executed within a price range of HKD 18.94–20.46 per share, with a volume-weighted average cost of HKD 19.48 per share and a total outlay of HKD 0.96 million.

Following the transaction: • Issued shares (excluding treasury shares) declined by 0.0164% to 301.32 million. • Treasury shares increased to 901,000, lifting the company’s total share count—including treasury stock—to 302.22 million. • All repurchased shares are being held in treasury; none have been cancelled.

The board’s repurchase mandate, approved on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases under this mandate now stand at 901,000 shares, representing 0.30% of the authorised limit and 0.2981% of the issued share base at the mandate date.

In accordance with Hong Kong Stock Exchange rules, CF PharmTech is restricted from issuing, selling, or transferring any shares until 20 June 2026, 30 days after the latest repurchase.